Assessment of Coronary Plaque Composition Using Optical Coherence Tomography

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Coronary AtherosclerosisEndothelial DysfunctionCoronary Small Vessel Disease
Interventions
DEVICE

Optical Coherence Tomography (C7 XR Dragonfly )

Evaluation of the coronary artery using Optical Coherence Tomography utilizing the Dragonfly OCT catheter following a clinically indicated angiogram and endothelial function testing with a positive diagnosis of endothelial dysfunction. The procedure is repeated following 6 months of Lp-PLa2 inhibition or placebo.

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Mayo Clinic

OTHER